Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
BACKGROUND
Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re-treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re-treatment was effective in patients with chronic plaque psoriasis.


OBJECTIVE
To describe the effects of tofacitinib withdrawal/re-treatment on health-related quality of life (HRQoL) and disease symptoms measured by patient-reported outcomes (PROs).


METHODS
The study was divided into initial treatment, treatment withdrawal, and re-treatment periods. Initial treatment: patients were randomized to receive tofacitinib 5 (n = 331) or 10 mg (n = 335) BID for 24 weeks. Treatment withdrawal: patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI) score from baseline and Physician's Global Assessment of 'clear'/'almost clear' at Week (W)24 received placebo (withdrawal) or the previous dose (continuous treatment). Re-treatment: at relapse (> 50% loss of W24 PASI response) or at W40, patients received their initial tofacitinib dose. PROs included: Dermatology Life Quality Index (DLQI), Itch Severity Item (ISI), Short Form-36 (SF-36) and Patient's Global Assessment (PtGA).


RESULTS
After initial treatment with tofacitinib 5 and 10 mg BID, substantial and significant improvements were reported for mean DLQI (baseline: 12.6 and 12.6; W24: 5.1 and 2.6) and ISI (baseline: 6.7 and 6.9; W24: 2.9 and 1.6). Patients continuously treated with tofacitinib 5 and 10 mg BID maintained those improvements through Week 56 (DLQI: 3.0 and 2.1; ISI: 2.3 and 1.4). By W40, patients withdrawn from tofacitinib 5 and 10 mg BID showed worsening in DLQI (5.0 and 6.2) and ISI (3.7 and 4.0) scores; improvements were regained upon re-treatment (W56, DLQI: 3.4 and 2.4; ISI: 2.2 and 1.6). Similar results were reported for PtGA and SF-36.


CONCLUSIONS
Continuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re-treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.
The Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
C E M
CE
Griffiths
Dermatrials Research Inc, Hamilton, ON, Canada.
R
R
Vender
UCLA School of Medicine, Los Angeles, CA, USA.
H
H
Sofen
Icahn School of Medicine at Mount Sinai, New York, NY, USA.|Indiana School of Medicine, Indianapolis, IN, USA.|DermResearch PLLC, Louisville, KY, USA.
L
L
Kircik
Pfizer Inc, Global Innovative Pharmaceuticals, Groton, CT, USA.
H
H
Tan
Pfizer Inc, Global Innovative Pharmaceuticals, Groton, CT, USA.
S T
ST
Rottinghaus
Pfizer Inc, Global Innovative Pharmaceuticals, Groton, CT, USA.
M
M
Bachinsky
Pfizer Inc, Collegeville, PA, USA.
L
L
Mallbris
Pfizer Inc, Global Innovative Pharmaceuticals, Groton, CT, USA.
C
C
Mamolo
D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D010880:Piperidines / Q000008:administration & dosage*; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D011788:Quality of Life; D012720:Severity of Illness Index
D003879:Dermatologic Agents; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib